-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-12-24
3020-OL:HK:HK-X DBMSCIUSA (HKD)
COMMON STOCK | Other |
Last Closing
USD 1375Change
+25.50 (+1.89)%Market Cap
N/AVolume
135.00Analyst Target
N/AN/A
Verdict
Values as of: 2024-12-24
COMMON STOCK | Other |
Last Closing
USD 1375Change
+25.50 (+1.89)%Market Cap
N/AVolume
135.00Analyst Target
N/AN/A
Verdict
There is no Profile data available for 3020-OL.HK.
Currency: HKD
Country : Hong Kong
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
1318:HK | Mao Geping Cosmetics Co Ltd |
-1.45 (-2.57%) |
USD 26.31B |
1863:HK | China Longevity Group Company .. |
N/A |
USD 1.17B |
8355:HK | I-CONTROL |
N/A |
USD 0.39B |
8343:HK | HongGuang Lighting Holdings Co.. |
-0.02 (-3.28%) |
USD 0.31B |
0648:HK | CHINA RENJ |
N/A |
USD 0.12B |
0400-OL:HK | COGOBUY |
+0.01 (+0.78%) |
N/A |
0259-OL:HK | YEEBO (INT'L H) |
N/A |
N/A |
0406-OL:HK | YAU LEE HOLD |
-0.03 (-3.00%) |
N/A |
0294-OL:HK | YANGTZEKIANG |
N/A |
N/A |
0419-OL:HK | JIUHAO HEALTH |
N/A |
N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
DXZ:CA | Dynamic Active U.S. Mid-C.. | 11.35 % | 0.87 % |
+0.01 (+0.05%) |
CAD 0.03B |
IHF | iShares U.S. Healthcare P.. | 7.93 % | 0.43 % |
+0.07 (+0.05%) |
N/A |
TETF | 6.19 % | 0.64 % |
N/A |
N/A | |
MID | American Century Mid Cap .. | 5.64 % | 0.00 % |
+0.42 (+0.05%) |
USD 0.08B |
BGU-U:CA | Bristol Gate Concentrated.. | 5.13 % | 0.00 % |
+0.21 (+0.05%) |
CAD 0.11B |
FHI-B:CA | CI Health Care Giants Cov.. | 4.97 % | 0.00 % |
N/A |
CAD 0.05B |
IAI | iShares U.S. Broker-Deale.. | 4.14 % | 0.42 % |
+2.21 (+0.05%) |
N/A |
PSL | Invesco DWA Consumer Stap.. | 3.17 % | 0.60 % |
+1.05 (+0.05%) |
USD 0.10B |
HDIV | 2.83 % | 0.00 % |
N/A |
N/A | |
TDOC:CA | TD Global Healthcare Lead.. | 2.04 % | 0.00 % |
+0.01 (+0.05%) |
CAD 0.09B |
RYH | 1.72 % | 0.40 % |
N/A |
N/A | |
IBCZ:F | iShares IV Public Limited.. | 1.21 % | 0.00 % |
N/A |
N/A |
HONR | 1.20 % | 0.65 % |
N/A |
N/A | |
VVL:CA | Vanguard Global Value Fac.. | 0.63 % | 0.40 % |
+0.31 (+0.05%) |
N/A |
SMD | 0.45 % | 0.10 % |
N/A |
N/A | |
ESGL | ESGL Holdings Limited Ord.. | 0.00 % | 0.40 % |
+0.08 (+0.05%) |
USD 0.05B |
JKH | iShares Morningstar Mid-C.. | 0.00 % | 0.30 % |
N/A |
N/A |
DRFU:CA | Desjardins RI USA Multifa.. | 0.00 % | 0.57 % |
+0.32 (+0.05%) |
CAD 5.97M |
SPVM | Invesco S&P 500 Value wit.. | 0.00 % | 0.39 % |
+0.43 (+0.05%) |
USD 0.09B |
RYF | 0.00 % | 0.40 % |
N/A |
N/A | |
WBIF | WBI BullBear Value 3000 E.. | 0.00 % | 1.05 % |
+0.16 (+0.05%) |
N/A |
XXM:CA | 0.00 % | 0.68 % |
N/A |
N/A | |
XMWD:LSE | Xtrackers MSCI World Swap.. | 0.00 % | 0.00 % |
+0.87 (+0.05%) |
N/A |
DBPD:F | Xtrackers - ShortDAX x2 D.. | 0.00 % | 0.00 % |
N/A |
N/A |
IMCG | iShares Morningstar Mid-C.. | 0.00 % | 0.00 % |
+0.70 (+0.05%) |
N/A |
Market Performance vs. Industry/Classification (Other) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 27.43% | 81% | B- | 80% | B- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 27.43% | 79% | B- | 78% | C+ | ||
Trailing 12 Months | |||||||
Capital Gain | 27.43% | 78% | C+ | 78% | C+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 27.43% | 75% | C | 76% | C+ | ||
Trailing 5 Years | |||||||
Capital Gain | 99.42% | 83% | B | 93% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 99.42% | 83% | B | 91% | A- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 17.17% | 78% | C+ | 77% | C+ | ||
Dividend Return | 17.17% | 76% | C+ | 75% | C | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 20.11% | 75% | C | 73% | C | ||
Risk Adjusted Return | 85.39% | 97% | N/A | 97% | N/A | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
There is nothing we particularly dislike